What is the most likely karyotype (chromosomal abnormality) finding in Burkitt's lymphoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Karyotype in Burkitt's Lymphoma

The most likely karyotype finding in Burkitt's lymphoma is t(8;14)(q24;q32), which represents the MYC-IGH translocation. 1

Cytogenetic Characteristics of Burkitt Lymphoma

Burkitt lymphoma (BL) has a characteristic cytogenetic profile involving the MYC gene on chromosome 8. The translocation t(8;14) is the hallmark genetic abnormality found in approximately 80% of Burkitt lymphoma cases 2. This translocation juxtaposes the MYC oncogene from chromosome 8q24 with the immunoglobulin heavy chain (IGH) locus on chromosome 14q32, resulting in MYC overexpression.

Primary and Variant Translocations in Burkitt Lymphoma

  • Primary translocation (80%): t(8;14)(q24;q32) [MYC-IGH]
  • Variant translocations (20%):
    • t(8;22)(q24;q11) [MYC-IGL]
    • t(2;8)(p12;q24) [IGK-MYC]

All these translocations result in the same functional outcome - deregulation and overexpression of the MYC oncogene, which drives the aggressive proliferation characteristic of Burkitt lymphoma 1, 2.

Distinguishing Features from Other Lymphoma Karyotypes

To understand why t(8;14) is the correct answer, it's important to differentiate it from the other karyotypes mentioned:

  • t(9;22) - This is the Philadelphia chromosome, characteristic of chronic myeloid leukemia and some acute lymphoblastic leukemias, not Burkitt lymphoma
  • t(14;18) - This translocation involves BCL2-IGH and is the hallmark of follicular lymphoma (found in approximately 85% of cases) 3
  • t(15;17) - This is pathognomonic for acute promyelocytic leukemia, not Burkitt lymphoma

Diagnostic Significance

The identification of MYC rearrangements through cytogenetic analysis is essential for the diagnosis of Burkitt lymphoma. According to European recommendations for cytogenomic analysis, Burkitt lymphoma is characterized by "t(8;14); MYC-IGH, and IGK/IGL variants, with no additional involvement of BCL2 or BCL6 or complex karyotype" 1.

The NCCN guidelines further emphasize that BLs generally exhibit a simple karyotype, with MYC translocation involving an immunoglobulin gene as their sole abnormality 1. This contrasts with diffuse large B-cell lymphoma (DLBCL), which typically has a more complex karyotype that may include various combinations of MYC, BCL2, and BCL6 rearrangements.

Clinical Implications

The presence of the t(8;14) translocation has important clinical implications:

  • Confirms the diagnosis of Burkitt lymphoma when integrated with morphological and immunophenotypic findings
  • Distinguishes true Burkitt lymphoma from Burkitt-like lymphoma with 11q aberration, which lacks MYC rearrangement 1
  • Helps differentiate BL from double-hit or triple-hit lymphomas that have MYC rearrangements along with BCL2 and/or BCL6 translocations

Molecular Mechanisms

The t(8;14) translocation in Burkitt lymphoma can occur through different molecular mechanisms:

  • In endemic BL (African type), the translocation often occurs during V-D-J recombination of immunoglobulin genes 4
  • In sporadic BL, the translocation frequently arises during immunoglobulin isotype-switching 4

In both cases, the end result is the same - constitutive activation of the MYC oncogene leading to uncontrolled cell proliferation.

In conclusion, while other chromosomal abnormalities may be present in some cases of Burkitt lymphoma, the t(8;14) translocation is the defining cytogenetic feature of this aggressive B-cell malignancy.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.